Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02449616 · ClinicalTrials.gov registry record · Phase 3
Evaluation of Repeat Administration of Purified Poloxamer 188
A Phase 3 study, sponsored by Mast Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 16
- Enrollment target
NCT02449616: Completed Phase 3 study, sponsored by Mast Therapeutics.
NCT02449616 is a Phase 3 study that has completed, run by Mast Therapeutics. The registered enrollment target is 16 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02449616, a Phase 3 study, has completed, sponsored by Mast Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety of repeat administration of MST-188 during vaso-occlusive crisis of sickle cell disease. Additionally, this study will evaluate the development of acute chest syndrome during VOC and re-hospitalization for recurrence of VOC.
Interventions
- DRUG MST-188
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2015-06 |
| Phase | Phase 3 |
What the finished NCT02449616 record still lists
NCT02449616 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which MST-188 is the first listed.
NCT02449616 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02449616 about?
NCT02449616 is a clinical study titled "Evaluation of Repeat Administration of Purified Poloxamer 188". The purpose of this study is to evaluate the safety of repeat administration of MST-188 during vaso-occlusive crisis of sickle cell disease. Additionally, this study will evaluate the development of acute chest syndrome during VOC and re-hospitalization for recurrence of VOC.
What is the current status of trial NCT02449616?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 16 participants. The study started on 2015-06.
What interventions are being tested in trial NCT02449616?
The interventions under investigation include: MST-188 (DRUG).
Who is sponsoring clinical trial NCT02449616?
This trial is sponsored by Mast Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02449616's enrollment target sits among peer trials
16 1974th of 2000 higher than 24 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia